Commentary|Videos|July 30, 2026

Oncology Pulsepoint: How Clinicians Should Navigate New Bladder-Preserving Therapies for NMIBC

Name: How Clinicians Should Navigate New Bladder-Preserving Therapies for NMIBC
Uploaded: 2026-07-30T18:50:25.820Z
Duration: 12 min 18 s
Description: In an interview with Pharmacy Times, Ming-Hei Tai, PharmD, BCOP, oncology pharmacist at William Beaumont University Hospital, discussed the expanding range of bladder-preserving treatments for non–muscle-invasive bladder cancer (NMIBC), while emphasizing that bacillus Calmette-Guérin (BCG) remains an important standard when administered at the appropriate dose and schedule.

Author(s)Ryu Kariyawasam-Chavez, Content Associate

In an interview with Pharmacy Times, Ming-Hei Tai, PharmD, BCOP, discusses emerging bladder-preserving therapies for NMIBC, the limitations of single-arm trial data, the continued role of BCG, and the clinical and operational factors that should guide treatment selection.

In an interview with Pharmacy Times, Ming-Hei Tai, PharmD, BCOP, oncology pharmacist at William Beaumont University Hospital, discussed the expanding range of bladder-preserving treatments for non–muscle-invasive bladder cancer (NMIBC), while emphasizing that bacillus Calmette-Guérin (BCG) remains an important standard when administered at the appropriate dose and schedule.